Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189719 · ClinicalTrials.gov registry record · Phase 3
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
A Phase 3 study of Esophageal Neoplasms, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 749
- Enrollment target
- 20
- Study locations
NCT03189719 is a Phase 3 study of Esophageal Neoplasms that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 749 participants, below the 1,426-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03189719, a Phase 3 study of Esophageal Neoplasms, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 749 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as first-line treatment in participants with locally advanced or metastatic esophageal carcinoma. The overall primary efficacy hypotheses are as follows: 1. In participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors are programmed cell death-ligand 1 (PD-L1)-positive (defined as combined positive score \[CPS\] ≥10), ESCC participants whose tumors are PD-L1 positive (CPS ≥10), and in all participants, overall survival (OS) is superior with pembrolizumab plus SOC chemotherapy compared with placebo plus SOC chemotherapy. 2. In participants with ESCC, participants whose tumors are PD-L1 positive (CPS ≥10), and in all participants, progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator is superior with pembrolizumab plus SOC chemotherapy compared with placebo plus SOC chemotherapy.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Placebo
- DRUG Cisplatin
- DRUG 5-FU
Study Locations (20)
Other
- Hospital Aleman ( Site 0605) - Buenos Aires
- Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0602) - Buenos Aires
- Sanatorio Allende - Cordoba ( Site 0604) - Córdoba
- Hospital Privado Centro Medico Cordoba ( Site 0601) - Córdoba
New York
- Roswell Park Cancer Institute ( Site 0004) - Buffalo
- Weill Cornell Medical College ( Site 0024) - New York
New South Wales
- Blacktown Hospital ( Site 2000) - Blacktown
- Liverpool Hospital. ( Site 2001) - Liverpool
California
- Kaiser Permanente Southern California ( Site 0003) - West Los Angeles
Illinois
- The University of Chicago Medical Center ( Site 0001) - Chicago
Kansas
- University of Kansas ( Site 0029) - Westwood
Maryland
- University of Maryland Medical Center ( Site 0013) - Baltimore
Massachusetts
- Dana Farber Cancer Center ( Site 0009) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 749 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2023-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03189719
The ClinicalTrials.gov registry entry for NCT03189719 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 749 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,426-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (47% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03189719 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, New York, New South Wales.
Frequently Asked Questions
What is clinical trial NCT03189719 about?
NCT03189719 is a clinical study titled "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)". The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as first-line treatment in participants with locally advanced or metastatic eso...
What is the current status of trial NCT03189719?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 749 participants. The study started on 2017-07-25. Estimated completion is 2023-07-10.
What conditions does trial NCT03189719 study?
This clinical trial studies the following conditions: Esophageal Neoplasms.
What interventions are being tested in trial NCT03189719?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Placebo (DRUG), Cisplatin (DRUG), 5-FU (DRUG).
Who is sponsoring clinical trial NCT03189719?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03189719 being conducted?
This trial has 20 study locations across California, Illinois, Kansas, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
RECRUITING
-
Mayo Clinic Upper Digestive Disease Survey
RECRUITING
-
Distribution of Lymph Node Metastases in Esophageal Carcinoma
RECRUITING
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.